Biomede

• Research type

  Research Study

• Full title

  Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication (Biomede)

• IRAS ID

  200571

• Contact name

  Sean Jennings

• Contact email

  researchgovernance@contacts.bham.ac.uk

• Sponsor organisation

  Gustave Roussy

• Eudract number

  2014-001929-32

• Clinicaltrials.gov Identifier

  NCT02233049

• Duration of Study in the UK

  6 years, 0 months, 1 days

• Research summary

  Biomede is an international, multicenter, randomised, open-label, adaptive, phase II trial of treatment for Diffuse Intrinsic Pontine Glioma (DIPG). This trial mandates a biopsy of the tumour to obtain the biological profile of the tumour. The allocation of treatment in each patient will be based on the specific biological tumour profile. Recruitment target is 80 patients in the UK, 250 in the EU with DIPG over 4 years. The initial agents to be studied based on biomarkers profile are; Dasatinib, Erlotinib and Everolimus as single agents combined with standard radiotherapy.

• REC name

  London - Fulham Research Ethics Committee

• REC reference

  16/LO/2141

• Date of REC Opinion

  8 Feb 2017

• REC opinion

  Further Information Favourable Opinion